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Abstract
Objective To compare the prognostic utility of the 2-[18F]
fluoro-2-deoxy-D-glucose (FDG) maximum standardized
uptake value (SUVmax), primary gross tumor volume
(GTV), and FDG metabolic tumor volume (MTV) for
disease control and survival in patients with head and neck
squamous cell carcinoma (HNSCC) undergoing intensity-
modulated radiotherapy (IMRT).
Methods Between 2007 and 2011, 41 HNSCC patients
who underwent a staging positron emission tomography
with computed tomography and definitive IMRT were
identified. Local (LC), nodal (NC), distant (DC), and
overall (OC) control, overall survival (OS), and disease-
free survival (DFS) were assessed using the Kaplan–Meier
product-limit method.
Results With a median follow-up of 24.2 months (range
2.7–56.3 months) local, nodal, and distant recurrences
were recorded in 10, 5, and 7 patients, respectively. The
median SUVmax, GTV, and MTV were 15.8, 22.2 cc, and
7.2 cc, respectively. SUVmax did not correlate with LC
(p = 0.229) and OS (p = 0.661) when analyzed by median
threshold. Patients with smaller GTVs (\22.2 cc) demon-
strated improved 2-year actuarial LC rates of 100 versus
56.4 % (p = 0.001) and OS rates of 94.4 versus 65.9 %
(p = 0.045). Similarly, a smaller MTV (\7.2 cc) corre-
lated with improved 2-year actuarial LC rates of 100 versus
54.2 % (p \ 0.001) and OS rates of 94.7 versus 64.2 %
(p = 0.04). Smaller GTV and MTV correlated with
improved NC, DC, OC, and DFS, as well.
Conclusion GTV and MTV demonstrate superior prog-
nostic utility as compared to SUVmax, with larger tumor
volumes correlating with inferior local control and overall
survival in HNSCC patients treated with definitive IMRT.
Keywords Head and neck cancer  PET/CT 
Standardized uptake value (SUV)  Gross tumor volume
(GTV)  Metabolic tumor volume (MTV) 
Intensity-modulated radiotherapy (IMRT)
Introduction
Radiation therapy (RT) is the mainstay of treatment for
early and locally advanced head and neck squamous cell
carcinoma (HNSCC). Improvements in identification of the
tumor volume of head and neck tumors using imaging such
as 2-[18F] fluoro-2-deoxy-D-glucose (FDG) positron emis-
sion tomography with computed tomography (PET/CT)
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have facilitated radiation treatment planning by improved
target volume delineation and more accurate target
localization, which is critical for intensity-modulated
radiotherapy (IMRT). Sharp dose gradients between the
high dose region targeted at the tumor and adjacent low-
dose normal tissue regions in IMRT improves the thera-
peutic ratio between tumor control and radiation related
toxicity, although this is reliant on the accurate identifi-
cation of the tumor extent. Yet despite advanced IMRT
techniques and integration of advanced radiological
imaging such as PET/CT, locoregional failure still occurs
in 30–50 % of locally advanced HNSCC largely within
the high dose region [1, 2]. Such variable treatment
responses argue for the need to characterize metrics that
allow the a priori identification of patients at high risk of
treatment failure and death.
Currently the American Joint Committee on Cancer
(AJCC) staging, which utilizes a uni-dimensional tumor
size, local anatomic invasion, nodal involvement, and
presence of metastatic disease, is the most widely accepted
and applied prognostic system in cancer [3]. Yet much
attention has been called to its weaknesses, specifically in
its ability to identify HNSCC patients at high risk of
recurrence [4–6]. PET/CT has been increasingly integrated
into diagnostic staging and radiation planning for HNSCC
[7, 8], and has been demonstrated to be an accurate and
sensitive imaging modality for the post-treatment evalua-
tion of patients with HNSCC compared to clinical exam
and CT alone [9, 10]. More, recently PET/CT variables
including maximum standardized uptake value (SUVmax)
and metabolic tumor volume (MTV) are emerging as
potential radiological biomarkers in patients with HNSCC
[11–17].
Volumetric indices have been proposed to risk stratify
patients. Studies have reported that the primary gross
tumor volume (GTV) correlates with outcomes and sur-
vival in patients with HNSCC undergoing curative sur-
gery [18], radiation [19–21], or combined chemoradiation
treatments in various head and neck cancer sites [4–6,
22, 23]. Given the interest in PET-based imaging the
MTV has been recently explored as a combined volu-
metric and metabolic radiological biomarker. Studies
have reported the predictive power of MTV in patients
with head and neck cancer undergoing chemoradiation
[12, 13].
The relative importance between SUVmax, GTV, and
MTV of the primary tumor in the risk stratification of
HNSCC patients has not been determined. This retrospec-
tive study sought to compare the prognostic utility of
SUVmax, GTV, and MTV with respect to disease outcome
and survival in patients with HNSCC undergoing IMRT
with or without concomitant chemotherapy.
Materials and methods
Patient selection
The study was conducted as a retrospective review
approved by the institutional review board (IRB). Informed
consent was waived by the IRB. Fifty-one newly diagnosed
HNSCC patients treated between January 2007 and March
2011 underwent IMRT (with or without chemotherapy) and
had PET/CT imaging obtained prior to start of IMRT.
Forty-one patients met the inclusion criteria. In total 10
patients were excluded: 6 had synchronous or metachro-
nous malignancies within 3 years prior to HNSCC diag-
nosis, 2 had unknown primary, 1 had sino-nasal cancer, and
1 died shortly after treatment from non-cancer related
causes (sepsis). All patients were staged according to the
2002 AJCC classification [24].
PET/CT protocol
All PET/CT studies were performed on a GE Discovery
STE 16 (General Electric, Milwaukee) PET/CT scanner.
Patients were scanned skull base to mid-thigh in treatment
position on a flat table. Patients were injected with an
average of 13.6 ± 3.3 mCi of 18F-FDG and incubated for
an average period of 63.0 ± 5.9 min. The amount of
injected radioactivity was routinely measured by quantifi-
cation of the radioactivity of the syringe before and after
injection. All patients were scanned using a dedicated head
and neck protocol. Head and neck images were acquired
with the arms down and body images were obtained with
arms up from clavicle to mid-thigh. Body images were
obtained first, followed by head and neck images and then
low-dose deep inspiration images of the chest.
The dedicated head and neck PET scans were done
using 2D imaging with emission scans lasting between 5
and 6 min, and a field of view (FOV) of 30 cm. The matrix
size was 128 9 128, and slice thickness was 3.3 mm. The
CT images were obtained with a matrix of 512 9 512.
Beam collimation was 10 mm with a pitch of 0.984. Table
speed was 9.84 mm/rotation and the slice thickness was
0.625 mm. kV of 120 and mAs of 440 were used. Intra-
venous contrast (IV) was administered by power injection
(GE electric, Milwaukee) of 60 ml of Optiray IV (Tyco
Health care/Mallinckrodt, Hezelwood) after a 40 s delay
for the head and neck images. There was a second bolus
after a 110 ml of IV contrast was given for the body section
of the study. CT images were reconstructed to the PET
slice thickness to match the PET and to create fused ima-
ges. In addition, CT images were reconstructed at 1.25 mm
with 1.25 mm spacing in soft tissue and bone algorithm for
review.
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PET/CT image analysis
All PET/CT studies were electronically retrieved from
archives and reviewed on a GE Advantage Workstation by
a single, board-certified radiologist with neuroradiology
and nuclear medicine fellowship training. PET, CT, and
fused PET/CT images were displayed in axial, coronal, and
sagittal planes. For the purposes of this study, the relevant
imaging parameter measurements were the primary tumor
SUVmax and MTV segmented from PET. MTV was defined
as the tumor volume with FDG uptake segmented by a
gradient-based method. The commercially available
MIMvista software analysis suite (MIM Software Inc.,
Cleveland, OH) includes a contouring suite for radiation
therapy planning and a PET/CT fusion suite. Once the
primary tumor (target) was segmented, SUVmax and MTV
were automatically calculated by the MIMvista software.
The gradient and threshold segmentation methods of vol-
ume measurement available in MIMvista software previ-
ously described rely on an operator-defined starting point
near the center of the lesion [25, 26]. As the operator drags
the cursor out from the center of the lesion, six axes extend
out, providing visual feedback for the starting point of
gradient segmentation. Spatial gradients are calculated
along each axis interactively, and the length of an axis is
restricted when a large gradient is detected along that axis.
The six axes define an ellipsoid that is then used as an
initial bounding region for gradient detection. The MTV
and SUVmax within the bounding region are automatically
calculated.
IMRT treatment planning
Patients underwent CT simulation (Brilliance CT Big Bore,
Philips Medical Systems, Cleveland, OH) in the supine
position immobilized with a custom thermoplastic mask.
The radiation planning CT acquisition encompassed the
vertex of the scalp to at least 5 cm below the clavicle using
2–3 mm slice thickness. Treatment planning was per-
formed using Philips Pinnacle3 software suite (version 6.0
to 8.0m, Philips Medical Systems, Fitchburg, WI). GTVs
were contoured incorporating diagnostic CT, PET, and/or
MR images. To aid GTV contouring, PET/CT images were
fused using Philips Pinnacle3 software suite prior to 2008
or MIMVista version 5.1.2 (MIMVista Corp., Cleveland,
OH) after 2008. Structures on the planning CT contoured
by the physician included: GTV, clinical target volume
(CTV), planning target volume (PTV), and organs at risk
including critical normal tissue organs adjacent to the tar-
get volumes. GTVs were manually contoured for IMRT by
a single board-certified radiation oncologist and the vol-
umes were then calculated by the software when generating
dose volume histograms. No auto segmentation was used to
create GTVs. Volumetric expansions from GTV to CTV
were 7–15 mm (respecting normal tissue planes) followed
by a 3–5 mm expansion to PTV. IMRT plans were
designed with seven to ten 6 mv photon beams, using an
inverse optimization algorithm with normalization such
that 95 % of PTV was covered with the prescription dose
(66–70 Gy), with the goal of no more than 1 % of PTV
receiving less than 93 % of prescription dose, and no more
than 1 % or 1 cc of the tissue outside the PTV receiving
more than 110 % of prescription dose. Elective nodal areas
and regions at risk for subclinical disease were treated to
54–60 Gy using a dose painting technique.
Treatment
All patients were treated with definitive IMRT. The GTV
was treated to a median dose of 69.96 Gy (range
66.0–69.96 Gy), over a median of 33 fractions (range
32–33), and a median of 48 days (range 39–72 days).
Concurrent chemotherapy was given to 36 (87.8 %)
patients: 23 received cisplatin, 8 received carboplatin, and
5 received cetuximab. Of these 36 patients 15 also received
induction chemotherapy.
Follow-up
Patients were followed after the conclusion of treatment,
continuing until analysis or patient death. PET/CT was
used to assess clinical response in addition to clinical exam
at 3 months as part of standard treatment care. Disease
recurrence was defined as the first site of failure including
local failure, nodal failure or distant failure. All failures
were confirmed by biopsy.
Statistical analysis
The statistical endpoints analyzed in this study were local
control (LC), nodal control (NC), distant control (DC),
overall control (OC), overall survival (OS) and disease-free
survival (DFS), measured from the end of IMRT to the date
of event, censoring patients at last follow-up or death. For
OC, the event is occurrence of first local, nodal, or distant
relapse. Overall survival was defined as death due to any
cause, DFS included patients who died or had disease
relapse anytime after the end of IMRT.
The Kaplan–Meier product-limit method was used to
estimate the probabilities of tumor control and survival
rates at 2 years irrespective of follow-up length [27]. The
comparison of survival rates among the groups was done
using the two-tailed log rank test. A probability value of
less than 0.05 was considered statistically significant. All
other statistical computations were performed on SAS 9.1
system (SAS Institute, Cary, NC).
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Results
Patients and tumor characteristics
Non-white patients comprised 61 % of patient cohort, with
71 % of patients presenting with stage IV disease. The
overall median follow-up was 24.2 months (range 2.7–56.3
months) and 27.1 months (range 4.0–56.3) among surviving
patients. Complete patient and tumor characteristics are
described in Table 1. For the patient cohort the median
SUVmax of the primary tumor was 15.8 (range 4.5–33.8), the
median GTV was 22.2 cc (range 1.5–162.5 cc), and the
median MTV was 7.2 cc (range 0.40–43.5 cc). Overall and
sub-site specific PET/CT and tumor volume characteristics
are described in Table 2.
Disease control and patterns of failure
Local, nodal, and distant recurrences occurred in 10, 5, and
7 patients, respectively, with a median time to recurrence
of 2.4 months. The median time to local, nodal, and distant
failure was 2.9, 2.2, and 2.2 months, respectively. The
estimated 2-year actuarial LC rate was 77.7 %, NC rate
was 87.7 %, and the DC rate was 82.0 %. The estimated
actuarial DFS and OS rates at 2 years were 67.6 and
79.8 %, respectively, Table 3.
SUV parameters, tumor volume and treatment outcome
Table 3 describes the LC, NC, DC, OC, OS, and DFS of
the patient cohort dichotomized by median SUV parame-
ters and tumor volume measurements. SUVmax (\15.8 vs.
C15.8) showed a non-significant trend for DC (95.0 vs.
69.7 %, p = 0.053). A smaller GTV (median cutoff
of\22.2 cc) was associated with improved disease control
and survival for all treatment outcomes including LC
(100.0 vs. 56.4 %, p = 0.001) and OS (94.4 vs. 65.9 %,
p = 0.045), Figs. 1, 2. A similar result was noted for
MTV where patients with smaller MTVs (median cutoff
of \7.2 cc) had improved LC and OS as compared to
Table 1 Patient characteristics of 41 head and neck cancer patients
Median Mean ± SD Range
Age (years) 57.0 58.9 ± 10.3 31–86
Smoking (pack-years) 35.0 37.3 ± 25.4 0–100


























SD standard deviation, n number of patients, AJCC American Joint
Committee on Cancer
Table 2 PET/CT and tumor volume characteristics of 41 head and
neck cancer patients
n Median Mean ± SD Range
SUVmax
Overall 41 15.8 16.0 ± 6.9 4.5–33.8
Oral cavity 3 18.3 17.0 ± 3.3 13.2–19.5
Nasopharynx 5 13.5 12.1 ± 5.2 4.5–17.3
Oropharynx 18 16.2 15.9 ± 6.6 5.9–32.4
Hypopharynx 4 25.0 24.4 ± 8.3 13.9–33.8
Larynx 11 11.0 14.4 ± 6.6 7.6–23.4
GTV (cc)
Overall 41 22.2 33.1 ± 34.1 1.5–162.5
Oral cavity 3 32.6 44.3 ± 20.9 32.0–68.4
Nasopharynx 5 15.5 20.4 ± 13.7 8.0–39.5
Oropharynx 18 16.3 27.6 ± 29.3 1.5–108.2
Hypopharynx 4 53.7 53.9 ± 38.1 9.1–99.2
Larynx 11 22.0 37.2 ± 47.2 3.3–162.5
MTV (cc)
Overall 41 7.2 11.2 ± 11.9 0.40–43.5
Oral cavity 3 17.2 20.0 ± 12.2 9.4–33.4
Nasopharynx 5 3.7 4.6 ± 3.5 0.90–9.2
Oropharynx 18 5.3 11.7 ± 13.0 0.40–40.9
Hypopharynx 4 9.2 13.9 ± 10.5 7.7–29.6
Larynx 11 5.7 10.2 ± 12.8 0.50–43.5
SUVmax maximum standardized uptake value, GTV gross tumor vol-
ume, MTV metabolic tumor volume, cc cubic centimeters
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patients with larger MTV; LC (100.0 vs. 54.2 %,
p \ 0.001) and OS (94.7 vs. 64.2 %, p = 0.040), Figs. 3, 4.
Correlating T category, AJCC stage with SUV
parameters and tumor volume
There was a significant correlation between GTV and MTV
with a Pearson correlation coefficient of 0.53 (p \ 0.0004).
Smaller GTV (\22.2 cc) was associated with lower MTV
(4.0 vs. 18.1 cc, p \ 0.001). A significant association was
also found between tumor volume measurements and SUV
parameters with larger tumor volume associated with
greater SUVmax, Table 4.
AJCC stage correlated with SUVmax, but not GTV and
MTV though number of patients with stage I, II and III
disease were fewer. Compared to patients with AJCC stage
I–III disease, stage IV disease patients had higher values of
SUVmax (11.9 vs. 17.7, p = 0.013), larger GTV (19.8 vs.
38.6 cc, p = 0.109), and larger MTV (4.1 vs. 14.2 cc,
p = 0.012). A non-significant trend was noted for SUVmax,
GTV, and MTV with increasing T stage, Table 4.
Discussion
This study demonstrates that both GTV and MTV are
superior prognostic radiological biomarkers of treatment
outcome and survival for HNSCC patients undergoing
definitive IMRT as compared to SUVmax. Improved local,
nodal, and overall control rates were seen in patients with
smaller GTV and MTV. SUVmax was found to correlate
significantly with AJCC stage, GTV and MTV, although in
this study it was not found to be prognostic for outcome.
Table 3 PET/CT parameters, tumor volume and survival and disease control status








Median n Events (2-year actuarial control rates)
All subjects
41 10 (77.7 %) 5 (87.7 %) 7 (82.0 %) 13 (70.3 %) 14 (79.8 %) 18 (67.6 %)
SUVmax
\15.8 20 3 (90.0 %) 1 (95.0 %) 1 (95.0 %) 4 (85.0 %) 5 (88.7 %) 7 (78.9 %)
C15.8 21 7 (66.0 %) 4 (80.7 %) 6 (69.7 %) 9 (57.1 %) 9 (71.4 %) 11 (57.1 %)
p value 0.229 0.179 0.053 0.178 0.661 0.506
GTV (cc)
\22.2 20 0 (100.0 %) 0 (100.0 %) 1 (94.4 %) 1 (94.4 %) 4 (94.4 %) 5 (88.9 %)
C22.2 21 10 (56.4 %) 5 (75.9 %) 6 (70.3 %) 12 (47.6 %) 10 (65.9 %) 13 (47.6 %)
p value 0.001 0.021 0.032 0.0004 0.045 0.009
MTV (cc)
\7.2 21 0 (100.0 %) 0 (100.0 %) 0 (100.0 %) 0 (100.0 %) 4 (94.7 %) 4 (94.7 %)
C7.2 20 10 (54.2 %) 5 (74.7 %) 7 (61.1 %) 13 (39.4 %) 10 (64.2 %) 14 (39.4 %)
p value 0.0003 0.015 0.002 \0.0001 0.040 0.001
Fig. 1 Local control according to median gross tumor volume (GTV)
Fig. 2 Overall survival according to median gross tumor volume
(GTV)
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Schwartz et al. [28] evaluated 54 patients with HNSCC,
undergoing definitive RT including postoperative patients
with or without concurrent chemotherapy, and reported that
a SUV of greater than 9, the median, significantly corre-
lated with inferior local control and disease-free survival.
On univariate and multivariate analyses these data
remained significant or borderline significant. Similarly,
Machtay et al. [14] reported in a cohort of 60 HNSCC
patients, treated with definitive radiotherapy with or with-
out concurrent chemotherapy, that an SUVmax \9, median
SUVmax of the study was 7.2, was associated with
improved 2-year DFS of 72 versus 37 % (p = 0.007).
Torizuka et al. [15] reported in 50 consecutive HNSCC
patients who underwent definitive RT with or without
chemotherapy, or surgery with or without postoperative RT
that an SUVmax of B7 significantly predicted higher rates
of 2 year local control and disease-free survival. When
adjusted for age and nodal stage these findings remained
significant. However, the median SUVmax for the cohort
was 10.53, and they did not identify how an SUV max of 7
was selected as the optimal cut point. Limitations of
comparing SUV as a radiological biomarker between
studies includes the use of different SUV cutoff values
which may be influenced by multiple factors including
patient selection, differences in imaging technique, injected
FDG dose, incubation period, protocol, scanner, and
reconstruction algorithm variation [29–31].
Our study confirms the findings of Strongin et al. [22]
who reported a series of 78 patients with stage III–IV
oropharyngeal, laryngeal or hypopharyngeal cancer, in
which patients with locoregional failure had greater tumor
volumes than patients free of disease (58 vs. 36.5 cc,
p = 0.028), and those with a GTV\35 cc had significantly
improved overall control (71 vs. 41 %), progression free
survival (61 vs. 33 %), and overall survival (84 vs. 41 %)
rates. Chen et al. [6] demonstrated that a primary tumor
volume of greater than 60 cc in patients with nasopha-
ryngeal cancer is superior to the AJCC and the TNM
classification system when correlated with survival rates in
patients with nasopharyngeal cancer who underwent
definitive RT. Similarly, Studer et al. [4] reported that a
GTV-based staging system was superior to TNM and
Fig. 3 Local control according to median metabolic tumor volume
(MTV)
Fig. 4 Overall survival according to median metabolic tumor volume
(MTV)
Table 4 SUVmax, GTV, MTV by AJCC stage and tumor stage
SUVmax GTV (cc) MTV (cc)
n Mean ± SD
AJCC Stage
I 2 6.8 ± 1.3 5.1 ± 2.0 2.5 ± 0.43
II 4 9.0 ± 4.2 30.4 ± 45.9 4.6 ± 3.0
III 6 15.6 ± 6.1 17.7 ± 11.0 4.4 ± 2.8
IV 29 17.7 ± 6.5 38.6 ± 35.7 14.2 ± 13.0
p value 0.018 0.350 0.104
I–III 12 11.9 ± 6.1 19.8 ± 26.7 4.1 ± 2.6
IV 29 17.7 ± 6.5 38.6 ± 35.7 14.2 ± 13.0
p value 0.013 0.109 0.012
Tumor category
T1 5 10.1 ± 5.7 10.5 ± 5.8 2.3 ± 1.0
T2 8 14.9 ± 4.4 28.5 ± 35.6 9.1 ± 13.1
T3 13 17.1 ± 6.5 27.3 ± 29.7 9.3 ± 11.1
T4 15 17.5 ± 8.0 48.1 ± 38.2 17.0 ± 12.0
p value 0.171 0.129 0.066
GTV (cc)
\22.2 20 13.5 ± 5.6 N/A 4.0 ± 4.2
C22.2 21 18.4 ± 7.2 18.1 ± 12.8
p value 0.021 \0.0001
MTV (cc)
\7.2 21 12.8 ± 5.1 11.7 ± 7.6 N/A
C7.2 20 19.3 ± 7.0 55.6 ± 36.8
p value 0.002 \0.0001
N/A not applicable
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AJCC systems in correlating overall survival in patients
with any site, except laryngeal HNSCC undergoing defin-
itive IMRT.
The current study demonstrated that the clinical GTV
based on PET/CT and clinical examination, appears to be
prognostic as it correlates with control and survival in
HNSCC patients who were treated with definitive IMRT
with and without induction and/or concurrent chemother-
apy regimens. Given the expanding interest in metabolic
and volumetric-based indices, we evaluated the prognostic
utility of MTV, defined as the volume of tumor with FDG
avidity. Chung et al. [12] reported on 64 patients with
pharyngeal cancer undergoing definitive radiation therapy
with or without concomitant chemotherapy. Patients with a
MTV greater than 40 cc, a statistically optimized cut point,
indicated a significantly worse disease-free survival than
those with MTV B40 cc (HR 3.42, p = 0.04) using a raw
SUV cutoff of 2.5 to define MTV within a radiologist
contoured margin of the primary tumor and areas of nodal
disease. La et al. [13] recently demonstrated the predictive
value of MTV in patients with head and neck cancer
undergoing chemoradiation. MTV was defined by auto-
segmentation in three dimension of volume with 50 % or
greater SUVmax using custom software on pretreatment
PET scans [13]. An increase in MTV of 17.4 cc or greater
correlated with recurrence or death. MTVs correlated with
the GTV with a correlation coefficient of 0.73, but con-
sistently underestimated GTV, which was a finding con-
firmed in our study [13]. Similar to our findings, these
studies failed to demonstrate a correlation with SUVmax
and DFS or OS.
Given the ability of autosegmentation algorithms, MTV
has potential to become a standardized prognostic metric.
We suspect that interest in the standardization of MTV will
continue to grow as new algorithms are developed, but it is
critical to understand the current limitations of MTV as a
metric including the lack of a standardized SUV threshold,
lack of true correlation with anatomic structures, validation
of autosegmentation software, and variability in SUV
cutoffs. The impact of these limitations were clearly
demonstrated by Ford et al. [32] who reported that a 5 %
change in threshold contour can translate into a 200 %
increase in contour volume resulting in a significant dosi-
metric effect. Furthermore, MTV has significant limitation
in defining target volumes for treatment planning and using
the MTV for treatment planning purposes alone could risk
marginal treatment failure as it may underestimate the
tumor volume. In contrast, GTV integrates multiple infor-
mation including radiological and clinical examination
findings.
In summary, GTV and MTV demonstrate superior
prognostic utility as compared to SUVmax as patients with
larger tumor volumes are associated with significantly
inferior control and survival in HNSCC patients treated
with definitive IMRT.
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